Search research articles
Contact Us
Filters
Showing results (431-440 of 738) with videos related to
Page
of 74
Sort By:
The Lancet. Oncology
|
June 18, 2021
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
Eric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A Ledermann, et al.
Cancer
|
April 15, 2023
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Mansoor R Mirza, Antonio González-Martín, Whitney S Graybill, et al.
Gynecologic Oncology
|
October 27, 2023
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032)
Leslie M Randall, David M O'Malley, Bradley J Monk, et al.
The Lancet. Oncology
|
December 3, 2020
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
Rodney P Rocconi, Elizabeth A Grosen, Sharad A Ghamande, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study
B J Monk, M F Brady, C Aghajanian, et al.
Gynecologic Oncology
|
August 23, 2016
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 16, 2024
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy
Christof Vulsteke, Setsuko K Chambers, Maria Jesús Rubio Pérez, et al.
Gynecologic Oncology
|
February 7, 2024
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
Bhavana Pothuri, Sileny Han, Dana M Chase, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 31, 2023
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)
Rebecca C Arend, Bradley J Monk, Ronnie Shapira-Frommer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2010
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer
Bradley J Monk, Thomas J Herzog, Stanley B Kaye, et al.
Page
of 74
Search research articles
Search
Showing results (431-440 of 738) with videos related to
Sort By:
Page
of 74
The Lancet. Oncology
|
June 18, 2021
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
Eric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A Ledermann, et al.
Cancer
|
April 15, 2023
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Mansoor R Mirza, Antonio González-Martín, Whitney S Graybill, et al.
Gynecologic Oncology
|
October 27, 2023
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032)
Leslie M Randall, David M O'Malley, Bradley J Monk, et al.
The Lancet. Oncology
|
December 3, 2020
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
Rodney P Rocconi, Elizabeth A Grosen, Sharad A Ghamande, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study
B J Monk, M F Brady, C Aghajanian, et al.
Gynecologic Oncology
|
August 23, 2016
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 16, 2024
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy
Christof Vulsteke, Setsuko K Chambers, Maria Jesús Rubio Pérez, et al.
Gynecologic Oncology
|
February 7, 2024
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
Bhavana Pothuri, Sileny Han, Dana M Chase, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 31, 2023
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)
Rebecca C Arend, Bradley J Monk, Ronnie Shapira-Frommer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2010
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer
Bradley J Monk, Thomas J Herzog, Stanley B Kaye, et al.
Page
of 74